EPS for Opiant Pharmaceuticals Inc (OPNT) Expected At $-0.87

October 13, 2017 - By Darrin Black

 EPS for Opiant Pharmaceuticals Inc (OPNT) Expected At $ 0.87

Analysts expect Opiant Pharmaceuticals Inc (NASDAQ:OPNT) to report $-0.87 EPS on October, 30.They anticipate $0.35 EPS change or 67.31 % from last quarter’s $-0.52 EPS. After having $-1.55 EPS previously, Opiant Pharmaceuticals Inc’s analysts see -43.87 % EPS growth. The stock decreased 5.37% or $2.05 during the last trading session, reaching $36.11. About shares traded. Opiant Pharmaceuticals Inc (NASDAQ:OPNT) has 0.00% since October 13, 2016 and is . It has underperformed by 16.70% the S&P500.

Opiant Pharmaceuticals, Inc., formerly Lightlake Therapeutics, Inc., is a specialty pharmaceutical company. The company has market cap of $73.18 million. The Firm develops pharmacological treatments for substance use, addictive and eating disorders. It has a 14.41 P/E ratio. The Firm has developed NARCAN Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA).

More notable recent Opiant Pharmaceuticals Inc (NASDAQ:OPNT) news were published by: Globenewswire.com which released: “Opiant Pharmaceuticals, Inc. Announces Listing on the Nasdaq Capital Market” on August 28, 2017, also Seekingalpha.com with their article: “Opiant Pharma continues rally, shares up 14%” published on September 06, 2017, Globenewswire.com published: “Opiant Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2017 Financial …” on March 16, 2017. More interesting news about Opiant Pharmaceuticals Inc (NASDAQ:OPNT) were released by: Globenewswire.com and their article: “Opiant Pharmaceuticals, Inc. Licenses Aegis Therapeutics’ Intravail® Drug …” published on June 28, 2017 as well as Globenewswire.com‘s news article titled: “Opiant Pharmaceuticals, Inc. Announces Phase I Data for OPNT002 in Development …” with publication date: July 19, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts

Twitter Auto Publish Powered By : XYZScripts.com